drugset / Trial / NCT01861613

Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students

NCT01861613

NaSingle-groupOpen-labelPrevention

Summary

At present, children less than 15 y of age have been regarded as a key group for hepatitis B immunization in China. However, there is not yet special immunization strategy for population above 15 y of age. In this study, we investigated the seroprevalence of hepatitis B and immune response to HB vaccine among Chinese college students to uncover the need on universal mass vaccination or booster immunization only for students with HBV vaccination history against hepatitis B in Chinese college students to inform decision making.

Timeline

Start
2009-09
Primary completion
2011-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Engerix-B Vaccine 20 ug/ml